General
Preferred name
Thallous Chloride
Synonyms
P&D ID
PD009258
CAS
15230-71-4
7791-12-0
5682-80-4
Tags
drug
contains metal
inorganic
Drug Status
approved
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ABSORPTION After IV administration, thallous chloride clears rapidly from the blood, with maximum concentration in the myocardium after about 10 min.; Only 5-8% of injected activity remained in the blood, following 5 minutes of intravenous administration.
HALF-LIFE 91% of the blood radioactivity has a t1/2 of 5 min.; 9% has t1/2 of 40 hours.
INDICATION For use as a diagnostic radiopharmaceutical.; It is indicated to help diagnose heart disease (eg, coronary artery disease, heart attack). It is also used for the diagnosis of parathyroid problems.
TOXICITY LD50 (mouse): 24 mg/kg.; Minimum lethal dose (Human): 8 mg/kg.; Thallium inhibits enzymes, but nothing is really known of a biochemical lesion. In fatal cases, there usually is extensive peripheral paralysis and cardiovascular involvement. The immediate cause of death may be peripheral respiratory failure of cardiac arrest.
Compound Sets
2
DrugBank
DB09316
DrugBank Approved Drugs
DB09316
External IDs
24
Properties
(calculated by RDKit )
Molecular Weight
241.96
Hydrogen Bond Acceptors
0
Hydrogen Bond Donors
0
Rotatable Bonds
0
Ring Count
0
Aromatic Ring Count
0
cLogP
-3.91
TPSA
0.0
Fraction CSP3
0.0
Chiral centers
0.0
Largest ring
0.0
QED
0.38
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Source data